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Abstract
Background: Poor response to anti-tumour necrosis factor biologicals like infliximab (IFX) is observed in patients
with ulcerative colitis (UC), which may lead to prolonged morbidity and waste of medical resources. We aimed to
look for potential biomarkers of response to IFX in patients with UC who were to undergo IFX induction therapy.
Methods: Seventy-two IFX naïve UC patients with partial Mayo (pMayo) score of 4–9 received IFX infusion at
weeks 0, 2 and 6 as induction therapy. The pMayo score, trough IFX and C-reactive protein (CRP) concentrations
were measured. At week 14, patients who achieved a pMayo score of ≤ 2 with no individual subscore exceeding
1 were judged as responders, while patients who responded, but did not achieve a pMayo score of ≤ 2 were
judged as partial responders. Likewise, patients who showed unchanged pMayo score or worsened were judged
as non-responders. Patients were followed for up to 3.3 years.
Results: Response, partial response and no response rates were 40.3, 33.3, and 26.4 %, respectively. CRP level at
week 2 in responders was significantly lower vs partial-responders (P = 0.0135) or non-responders (P = 0.0084) in
spite of similar trough IFX level. Further, the median CRP (week 2/week 0) ratio was significantly lower in patients
who responded vs partial-responders or non-responders, 0.06, 0.39 and 1.00, respectively. When the cut-off value
was set at 0.19 for the CRP (week 2/week 0) ratio, this ratio could predict partial-responders with 79.1 % sensitivity and
75.9 % specificity. Patients with the CRP (week 2/week 0) ratio greater than 0.19 were likely to be partial-responder,
with odds ratio 10.371 (P < 0.0001; 95 % confidence interval 3.596–33.440).
Conclusions: In this study, CRP level at week 2 following initiation of IFX induction therapy appeared to be a clinically
relevant biomarker of response to IFX in UC patients.
Background
The evolution of knowledge on the involvement of certain
cytokines, notably tumour necrosis factor (TNF)-α in the
immunopathogenesis of inflammatory bowel disease
(IBD) has stimulated the development of anti-TNF anti-
bodies as novel biologics for the treatment of IBD [1–3].
In deed, the efficacy of biologics like infliximab (IFX) in
both Crohn’s disease (CD) and ulcerative colitis (UC) has
led to a significant change in IBD treatment algorithms.
However, studies on the role of TNF-α in the exacerbation
of IBD have shown a greater focus on CD than on UC [3].
Nonetheless, an increased TNF-α level in the sera [4],
stool [5], and colonic mucosa [6] of patients with active
UC has been reported. Additionally, there are inconsistent
efficacy outcomes for IFX in patients with UC refractory
to corticosteroids, or to immunosuppressants [7, 8].
Serum C-reactive protein (CRP) is the most widely
studied acute phase protein in inflammatory diseases
and is found to have the best overall performance
among laboratory markers. CRP level correlates well with
disease activity in patients with CD [9, 10] and also in pa-
tients with UC [11]. The production of CRP is almost
exclusively in the liver by the hepatocytes as part of an
acute phase reaction in response to interleukin (IL)-6,
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TNF-α or IL-1β released from the site of inflammation.
Additionally, a marked reduction in the level of CRP
within 72 h of IFX infusion indirectly points to an effect
on the cytokine profile [12].
Recently, several investigators have shown interest in
understanding biomarkers of clinical response to IFX
including CRP levels in CD patients [13–18]. However,
their results were marred by inconsistencies; a high CRP
level at baseline was thought to predict response to IFX
[13, 14, 16], while a low CRP level at baseline was associ-
ated with sustained response [15]. Additionally, the re-
ported cut-off level for CRP was different in each study.
Further, in patients with CD [15, 17] or with UC [18],
CRP levels drop to normal value after completion of IFX
induction therapy and has been considered to predict sus-
tained remission. However, to our knowledge, prediction
of IFX responders, partial-responders or non-responders
following IFX induction therapy, especially at an early
stage of induction therapy has not been well investigated.
With this in mind, the present study was undertaken to
understand the predictive value of serum CRP at week 2
during induction therapy in IFX naïve patients with an
active flare of UC. Patients were then followed up over a 3
year period to observe the association of clinical outcome




From August 2010 to June 2011, patients with moderate
to severe UC refractory to corticosteroids and immuno-
suppressants were screened for IFX remission induction
therapy [1]. Moderate to severe UC was defined by non-
invasive components of Partial Mayo (pMayo) score of 4
to 9 [19]. Seventy-two eligible patients with active UC
were included in this study and then were followed up
to September 2013 to monitor their clinical outcomes.
IFX-infusion was scheduled at weeks 0, 2 and 6. The
infusion dose was set at 5 mg per kg bodyweight by
using 100 mg/unit vials. For example, if a patient’s body-
weight was 56 kg, he or she was to receive a total of 3
vials (300 mg).
Assessment of response to IFX
The clinical response to IFX was evaluated by measur-
ing the change in the pMayo score at week 14, which
was 8 weeks after the last IFX infusion. Patients who
achieved a pMayo score of ≤ 2, with no individual sub-
score exceeding 1 was judged as responder to IFX in-
duction therapy [20]. Patients who responded, but did
not achieve a pMayo score of ≤ 2 were judged as partial-
responders. Patients who showed an unchanged pMayo
score or worsened were judged as non-responders. Re-
sponders including partial responders could continue to
receive IFX infusion at an 8 week interval as maintenance
therapy.
Assays of serum functional IFX and CRP
Serum concentration of IFX that reflects binding cap-
acity of IFX to biotin-labeled TNF-α was measured by a
fluid-phase enzyme immunoassay reported by Yamada,
et al. [21]. Assay of IFX by this method yields results
similar to the monoclonal antibody-based enzyme im-
munoassay described by Cornillie, et al. [22]. Serum
CRP concentration was measured by rate nephrometry.
The lowest detectable concentration of CRP in this
assay is 0.01 mg/dL, while the normal cut-off value for
CRP is 0.3 mg/dL.
Ethical considerations
Our study protocol was reviewed and approved by Eth-
ics Committee at the Toho University Medical Centre.
Regarding the potential risks of IFX therapy, prior to
enrollment, patients were informed of the known, re-
ported adverse side effects in patients with UC. Prior to
IFX infusion, written informed consent was obtained
from all patients. Additionally, adherence was made to
the Principle of Good Clinical Practice and the Helsinki
Declaration at all times.
Statistics
When appropriate, data are presented as the median
and interquantile range. Statistical analyses were done
by the nonparametric Wilcoxon-Mann–Whitney test
for comparing the outcomes between 2 groups. Further,
qualitative data are analyzed by using the Fisher’s exact
test. CRP was tested for its relevance to predict IFX
partial-responders or non-responders by using receiver
operating characteristic (ROC) model curves. The over-
all performance of the ROC analysis was determined by
calculating the area under the curve (AUC). With the
aid of the ROC analysis, the cut-off value with optimal
sensitivity and specificity to predict partial-responders or
non-responders were also calculated. All P values are two-
tailed with the statistical significance set at P < 0.05, and
the analyses were done by using the statistical software
package (JMP, SAS Institute, Cary, NC).
Results
Clinical outcomes up to week 14
The clinical response rate for IFX induction therapy
following three infusions at weeks 0, 2, and 6 up to week
14 was 40.3 % (29 of 72 patients). The incidences of
partial-responder and non-responder were 33.3 % (24 of
72) and 26.4 % (19 of 72), respectively. Before week 14, 9
of 19 patients in the non-responder subgroup withdrew
from the study due to worsening UC (Fig. 1).
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Table 1 shows patients’ main demographic variables
at baseline. The median duration of UC was 4.1 years,
and the median dose of IFX (mg/kg/infusion) was 5.8.
The time from the initiation of IFX-induction therapy
due to UC flare-up was longer in the partial-responders
(P = 0.0255) or non-responders (P = 0.0072) vs responders;
107 days, 101 days and 38 days, respectively. Further, the
average serum albumin level was significantly lower in the
partial-responders (P = 0.0006) and the non-responders
(P = 0.0022) vs responder; 4.1 g/dL, 4.0 g/dL and 4.4 g/dL,
respectively. The average age was significantly shorter in
the non-responder sub-group as compared with the re-
sponders, 26.1 years vs 37.5 years (P = 0.0315). A higher
failure rate was seen for 2 or more immunosuppressants
in the past, 46.2 % in the non-responders vs 17.2 % in the
responders.
pMayo score, IFX and CRP levels at weeks 2 and 14
Two weeks after the first IFX infusion, we compared
trough IFX, pMayo score and CRP levels in the IFX re-
sponders with the corresponding values in the IFX
partial-responders and the non-responders. The pMayo
score and CRP levels in responders were significantly
lower than the levels in IFX partial-responders or non-
responders. However, trough IFX level between the re-
sponders and partial-responders or non-responders was
not significantly different (Table 2). Further, the ratio of
CRP at week 2/week 0 in the responder subg-roup was
significantly smaller than for IFX partial-responders or
non-responders, P = 0.0025 and P < 0.0001, respectively.
The same parameters and 3 individual subscores in the
Mayo score at week 14 (the final clinical efficacy evalu-
ation time point) are seen in Table 3. Differences in
these parameters between the 3 groups were almost the
same as shown in Table 2. The median CRP level from
week 2 to week 14 in the responder sub-group had de-
creased from 0.07 mg/dL to 0.04 mg/dL, while in the
partial-responder sub-group, CRP had increased from
0.19 mg/dL to 0.56 mg/dL. Only ten patients in the
non-responder sub-group could remain in the study up
to week 14.
The predictive value of CRP 2 weeks after starting IFX-
induction therapy
We applied a receiver operating characteristic (ROC)
curve model to test the relevance of CRP (week 2/week 0)
ratio to identify IFX partial-responder or non-responder
feature (Table 2). A cut-off value of 0.19 (week 2/week 0
ratio) on the ROC curve could predict an IFX partial-
responder feature with a 79.1 % sensitivity and 75.9 % spe-
cificity. The area under the ROC curve (AUC) which
reflected the overall performance of the ROC analysis was
0.799 (Fig. 2). Patients with the CRP (week 2/week 0) ratio
greater than 0.19 were likely to be partial-responder with
the odds ratio 10.371 (P < 0.0001; 95 % confidence interval
3.596–33.440). Further, we followed the ROC model for
baseline serum albumin level. If the cut-off value was set
at 4.1 g/dL, it could predict an IFX partial-responder
feature with 62.8 % sensitivity and 86.2 % specificity. How-
ever, baseline concentration of albumin did not appear to
be a sensitive predictor of response to IFX.
Fig. 1 Clinical outcomes in 72 patients up to week 14. All of the 72 eligible patients had active ulcerative colitis and were infliximab naïve at entry.
*Clinical response to infliximab was evaluated at week 14, patients could be divided into three subgroups: Responders (patients who achieved a partial
Mayo score of ≤ 2 with no individual subscore exceeding 1); partial-responder (patients who responded, but did not achieved a partial Mayo
score of ≤ 2 points); non-responders (patients in whom the partial Mayo score increased or remained unchanged relative to week 0). Only 10
of 19 patients in the non-responder sub-group were available for evaluation at week 14
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Week 2/week 0 CRP ratio, and the incidence of colectomy
We followed up the 72 patients for more than 3 years,
average 39.5 months after the initiation of IFX induction
therapy, focusing on the changes in the week 2/week 0
CRP ratio. The cumulative probability rates of proctoco-
lectomy in patients with the cut-off value of CRP (week 2/
week 0) ratio greater than 0.19, and patients with a lower
cut-off value were 20.5 and 4.8 %, respectively (Fig. 3).
Seven patients among the 40 who showed a cut-off value
greater than 0.19 in the CRP (week 2/week 0) ratio had
undergone proctocolectomy. Five patients were IFX non-
responders and two were partial-responders. Among these
7 patients, the mean time to undergo proctocolectomy
after the diagnosis of UC was 6.5 years, range 0.8 to
12.4 years. Only 1 patient among the 32 who showed a
lower than 0.19 cut-off CRP (week 2/week 0) ratio had
undergone proctocolectomy. This patient was responder
to IFX, but discontinued IFX-maintenance therapy due to
life-threatening pneumonia at 3.7 months after the initi-
ation of IFX induction therapy.
Table 2 Comparison of trough serum infliximab (IFX) levels, partial Mayo Score and C-reactive protein (CRP) levels in subgroups of
ulcerative colitis patients 2 weeks after the initiation of IFX infusion
Variable IFX responders (n = 29) IFX partial-responders (n = 24) IFX non-responders (n = 19) P1 Value P2 Value
Trough IFX (μg/mL) 23.3 [18.9–29.7] 30.9 [17.7–42.7] 25.0 [21.6–31.5] 0.1825 0.4436
Partial Mayo Score (0–9) 1.0 [0–3.0] 5.0 [3.0–6.0] 7.0 [3.0–8.0] <0.0001 <0.0001
CRP (mg/dL) 0.07 [0.02–0.24] 0.19 [0.08–0.67] 0.43 [0.16–2.13] 0.0135 0.0084
CRP (week 2/week 0) ratio 0.06 [0.02–0.21] 0.39 [0.08–0.97] 1.00 [0.29–1.89] 0.0025 <0.0001
Data are presented as the median [interquartile range] values and compared by Wilcoxon-Mann–Whitney test
P1, responder vs partial-responder; P2: responder vs no-responder
Table 1 Baseline demographic characteristics of the 72 patients with active ulcerative colitis (UC), sub-grouped as responders,
partial-responders or non-responders following infliximab (IFX) induction therapy
Demography IFX responders (n = 29) IFX partial-responders (n = 24) IFX non-responders (n = 19) P1 Value P2 Value
Male, number (%) 13 (44.8) 14 (58.3) 12 (63.2) 0.4117 0.2500
Age, year 37.5 [30.3–54.4] 37.6 [32.3–45.5] 26.1 [20.2–36.4] 0.9929 0.0315
Duration of UC, year 5.4 [1.8–9.3] 6.3 [2.6–10.4] 2.5 [1.0–6.1] 0.5028 0.0958
Duration (days) of active UC prior
to IFX induction
38.0 [26.5–63.0] 107.0 [30.5–178.8] 101.0 [41.0–153.0] 0.0255 0.0072
Dose of infused IFX (mg/kg) 6.2 [5.3–6.7] 5.7 [5.5–6.2] 6.1 [5.3–6.6] 0.4579 0.9411
CRP (mg/dL) 1.17 [0.41–2.74] 1.28 [0.32–2.11] 0.59 [0.26–1.16] 0.8302 0.1739
Albumin (g/dL) 4.4 [4.2–4.6] 4.1 [4.0–4.3] 4.0 [3.7–4.3] 0.0006 0.0022
Haemoglobin (g/dL) 12.3 [11.4–13.6] 12.8 [11.1–13.7] 11.9 [9.9–13.4] 0.9715 0.2820
Partial Mayo Score (0–9) 7 [5–7] 7 [6–8] 7 [5–7] 0.1020 0.8872
UC location, number (%)
Extensive 23 (79.3) 16 (66.7) 15 (79.0) 0.3579 1.0000
Left-sided 6 (20.7) 8 (33.3) 4 (21.1) 0.3579 1.0000
Corticosteroid dependent, number (%) 18 (62.1) 20 (83.3) 10 (52.6) 0.1274 0.5613
Corticosteroid refractory, number (%) 10 (34.5) 1 (4.2) 9 (47.4) 0.0075 0.5469
Concomitant medication, number (%)
5-Aminosalicylates 27 (93.1) 23 (95.8) 18 (94.7) 1.0000 1.0000
Corticosteroids 20 (69.0) 14 (58.3) 16 (84.2) 0.5662 0.3157
Azathioprine/ Mercaptopurine 8 (27.6) 6 (25.0) 6 (31.6) 1.0000 1.0000
Previously failed ≥2 immunosuppressant,
number (%)
5 (17.2) 1 (4.2) 8 (46.2) 0.2044 0.0959
Smoking status, number (%)
Currents smoker 2 (6.9) 3 (12.5) 1 (5.3) 0.6486 1.0000
Nonsmoker 24 (82.8) 21 (87.5) 14 (73.7) 0.7153 0.4873
Past smoker 3 (10.3) 0 (0) 4 (21.1) 0.2424 0.4116
Certain values are presented as the median [interquartile range] and compared by Wilcoxon-Mann–Whitney test. Categorical variables are represented as number
(%) and compared by the Fisher’s exact test. P1, responder vs partial-responder; P2, responder vs non-responder
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Discussion
In this study, we noticed that following the first IFX
infusion, serum CRP level at week 2 in IFX responders
significantly decreased relative to baseline, but a similar
trend was not observed in non-responders. Potentially
such observation should identify IFX responders at an
early stage during induction therapy. Therefore, at week
2, the pMayo score was significantly smaller in the IFX
responders vs partial-responders or non-responders, in
spite of trough IFX level not showing any significant
difference between these sub-groups. Further, the ratio
of serum CRP level at week 2/week 0 appeared to be
more meaningful than we had expected. Then we took
advantage of this finding and applied an ROC model to
see if the CRP ratio had any clinically relevant relationship
with IFX responder feature or otherwise partial-responder
and non-responders features. For the CRP ratio, a cut-off
value of 0.19 on the ROC graph predicted IFX partial-
responder feature with a 79.1 % sensitivity and 75.9 %
specificity. Finally, in patients with the cut-off value of the
CRP ratio being greater than 0.19, the cumulative prob-
ability of proctocolectomy was significantly higher than in
patients with a lower cut-off CRP ratio during the follow-
up period. Accordingly, changes in CRP at 2 weeks after
the initiation of IFX induction therapy may predict or be
associated with long-term clinical outcomes.
In the presented study, with respect to the clinical
response to IFX-induction therapy, patients could be
divided into 3 subgroups, responders, partial-responders
and non-responders when evaluated at week 14. These
clinical outcomes were associated with the changes in
serum CRP level at week 2 during IFX-induction ther-
apy. A marked reduction in the level of CRP within 72 h
of IFX infusion was reported as an effect on the cytokine
profile including IL-6 [12]. At this time, it is not possible
to explain if the reduction of CRP by IFX via an effect
on the cytokine profile is directly related to the observed
changes in the CRP (week 2/week 0) ratio. However, if
we accept that the therapeutic efficacy of IFX in UC is
via neutralization of TNF-α, then patients with UC may
be subdivided into those in whom TNF-α has a dominant
role in the exacerbation of the disease and those in whom
TNF-α does not have a major role, bearing in mind that
the exacerbation depends on other factors. If this assump-
tion is validated by sound clinical data, it should contrib-
ute to better treatment of UC.
Hitherto, other investigators have attempted to identify
predictors of clinical response to IFX in UC patients
[23–25]. A low TNF-α mRNA expression in the colorectal
mucosa at pre-treatment has been associated with better
clinical and endoscopic remission rates following IFX
induction therapy [23]. In contrast, patients who were
seropositive for perinuclear anti-neutrophil cytoplasmic
antibodies (pANCA) and were anti-saccharomyces cer-
evisiae antibodies negative (pANCA+/ASCA-) showed
significantly lower clinical response to IFX [24]. Fasanmade,
Table 3 Comparison of trough serum infliximab (IFX), C-reactive protein (CRP) levels, partial Mayo Score and subscores in subgroups
of patients with ulcerative colitis at week 14 following the initiation of IFX infusion
Variable IFX responders (n = 29) IFX partial-responders (n = 24) IFX non-responders (n = 10a) P1 Value P2 Value
Trough IFX (μg/mL) 12.4 [3.2–22.4] 9.1 [3.9–13.9] 17.6 [4.9–28.8] 0.8851 0.7274
CRP (mg/dL) 0.04 [0.01–0.07] 0.56 [0.27–0.96] 0.11 [0.02–0.50] 0.0009 0.01911
Partial Mayo Score (0–9) 0 [0–1] 4 [4–6] 6.5 [5.5–7.3] <0.0001 <0.0001
Stool frequency (0–3) 0 [0–0] 2 [2–3] 3 [2–3] <0.0001 <0.0001
Rectal bleeding (0–3) 0 [0–0] 1 [1–2] 2 [2–2.5] <0.0001 <0.0001
PGA (0–3) 0 [0–0] 1 [1–1] 2 [1.5-2] <0.0001 <0.0001
Data are presented as the median [interquartile range] values and compared by Wilcoxon-Mann–Whitney test. P1, responder vs partial-responder; P2, responder
vs non-responder
PGA Physician’s global assessment
a Only 10 of 19 patients were available for evaluation at week 14 visit, the other 9 had withdrawn due to worsened UC
Fig. 2 Receiver operating characteristic graphs to assess the
significance of C-reactive protein (week 2/week 0) ratio for the
prediction of infliximab partial-responder in patients with active
ulcerative colitis undergoing infliximab-induction therapy. A cut-off
value of 0.19 for C-reactive protein ratio on the receiver operating
characteristic graph could predict infliximab partial-responder feature
with a 79.1 % sensitivity and 75.9 % specificity
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et al. [25] reported that blood concentration of albumin
was associated with trough IFX levels and the response
to IFX. We did investigate the relevance of blood albu-
min levels to IFX efficacy in our ROC model, but found
that albumin level was not a sensitive predictor of re-
sponse to IFX. However, unlike albumin, in patients
with IBD, serum CRP level correlates well with disease
activity and is the most widely monitored laboratory
marker [9–11, 13]. Further, it has been reported that
patients with UC or CD in whom CRP level decreased
to normal range after completion of anti-TNF therapy
had better remission maintenance time [14, 17, 18].
Unlike, TNF-α mRNA, and serum (pANCA+/ASCA-),
measurement of CRP is an uncomplicated undertaking.
However, the prediction of clinical response to therapy
by the absolute value of CRP can be complicated due to
the deviation of CRP values between different laborator-
ies. Instead, application of the CRP ratio to judge clinical
outcomes is more appropriate because CRP ratio is less
affected by the differences between laboratories. The mini-
mum detectable concentration of CRP in the method we
used in this study is 0.01 mg/dL. Therefore, setting a cut-
off value of 0.19 for the CRP (week 2/week 0) ratio means
that patients with baseline CRP ≥ 0.05 mg/dL could be
factored into the assessments. However, 5 of 72 patients
had a baseline CRP value of <0.05 mg/dL. This means that
the CRP (week 2/week 0) ratio will not work as the pre-
dictor for approximately 7 % of patients.
At this point, we should state specific limitations
featured in this study. Firstly, the number of patients
included was not large enough to allow showing stron-
ger or otherwise weaker significance levels in our sub-
group comparisons. Secondly, patients with baseline
CRP value below 0.05 mg/dL could not be included in
the assessment of the CRP as predictor of response to
IFX. Thirdly, full endoscopy data was not included in
our analyses of clinical outcomes.
Conclusion
In this study, a significant difference in CRP between IFX
responders, partial-responders and non-responders during
IFX induction therapy was found 2 weeks following the
first IFX infusion. The differences in CRP (week 2/week0)
ratios between the responders, partial-responders and
non-responders were more striking than anything we had
expected. This was determined by the application of an
ROC model. This finding is potentially interesting in clin-
ical setting because monitoring the CRP (week 2/week 0)
ratio at an early stage like week 2 during IFX induction
therapy might provide an indication to stop futile anti-
TNF therapy.
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